Geier Asset Management’s iShares Biotechnology ETF IBB Stock Holding History

Geier Asset Management’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	$2.02M	Buy	12,336 +1	+0%	+$154	1.41%	23
2021 Q1	$1.91M	Buy	12,335 +11	+0.1%	+$1.75K	1.4%	22
2020 Q4	$1.93M	Buy	+12,324	New	+$1.76M	1.57%	20

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Geier Asset Management's IBB Position: Q2 2021 in Review

Geier Asset Management increased its iShares Biotechnology ETF (IBB) stake by 0.01% in Q2 2021, buying an estimated $154 and bringing the position to 12,336 shares worth $2.02M. The position accounts for 1.41% of the portfolio, ranked #23.

Geier Asset Management first reported a position in IBB in Q4 2020 and has held it in 3 quarters since. 863 funds tracked by Wall St. Rank hold IBB as of Q2 2021.

Geier Asset Management held 12,336 shares of iShares Biotechnology ETF worth $2.02M as of Q2 2021.
Geier Asset Management bought 1 iShares Biotechnology ETF share in Q2 2021, an estimated $154.
iShares Biotechnology ETF made up 1.41% of Geier Asset Management's portfolio in Q2 2021, its #23 holding.
Geier Asset Management first reported a position in iShares Biotechnology ETF in Q4 2020 and has held it in 3 quarters since.
863 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2021.

Based on Geier Asset Management's 13F filing for Q2 2021, filed 12 Jul 2021.